Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

MAGE-A3 as a Vaccine Target in NSCLC
Author
Howard (Jack) West, MD

One of the more intriguing presentations at ASCO this year was the one in which a novel vaccine against a protein called MAGE-A3 was tested in patients who underwent surgery and then received the vaccine post-operatively. What is MAGE-A3? It's a nearly tumor-specific antigen, which means that it's a protein seen almost exclusively on cancer cells, including lung cancer, head & neck, bladder, and melanomas. The only normal non-cancer tumor tissue it's seen on in the testicles, but there have been no problems with auto-immune or other complications against testicular tissue, as these cells don't have the capacity to generate an immune response.

The limited available evidence suggests that expression of MAGE-A3 is associated with a worse prognosis, and along with that is the finding that it's more commonly seen in higher cancer stages. It's seen in only about 16% of stage IA NSCLC tumors, about 35% of stage II and IIIA resected NSCLC tumors, and about 50% of more advanced NSCLC cancers.

The trial that made such a splash was presented by Vansteenkiste and colleagues (abstract here), and had a design of 2 to 1 randomization of patients after surgery to vaccine vs. placebo:

MAGE-A3 trial schema (click to enlarge)

The trial enrolled 182 patients with stage IB or II NSCLC and tumors that demonstrated MAGE-A3 expression (again, about 1/3 of those screened). The protocol was for the vaccine every three weeks for 5 cycles, followed by a maintenance phase of injections once every three months for two years. The total time of treatment was a little more than two years. The goal of the trial was to detect an improvement in the median time to recurrence (hopefully reducing the likelihood of the cancer recurring).

Typical for vaccines, the treatment was quite well tolerated, with the majority of side effects mild or moderate. Most were "local", meaning things like redness, swelling, and pain at the injection site, and some patients get fevers and other flu-like symptoms.

The trial demonstrated a 27% reduced risk of recurrence in the group that received the active vaccine:

MAGE A3 DFS curves

While this difference didn't quite reach statistical significance (p-value was a little higher than p = 0.05), that is a pretty encouraging improvement, and if the trial were just a little larger, this difference would have been statistically significant.

Based on these results, the manufacturer of the vaccine (GlaxoSmithKline) is moving forward with an international trial called MAGRIT in order to test the vaccine in approximately 2270 patients with MAGE-A3-positive stage IB, II, or IIIA resected tumors. Treatment can start directly after surgery, in patients who aren't good candidates for or just don't want post-op chemo, or patients can have received up to four cycles of platinum-based adjuvant chemotherapy. Unlike the smaller trial, patients on the larger phase III trial will be evenly divided between the active vaccine and placebo. The focus of the trial will be to detect a significant improvement in disease-free survival, and the planned enrollment will make it the largest post-operative NSCLC trial ever, which is particularly ambitious because only a fraction of the people screened for the trial will be eligible because of the requirement for MAGE-A3 expression on the tumor. Information on the trial, which is not yet enrolling patients but should be soon, is here.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancers OncTalk 2024
Video
  This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University Topics include: - Myeloma 101: Facts and Fiction of the 'Myeloma Marathon' - Updates in DLBCL - Treatment Basics of Bone Marrow Transplant - Frontline Therapies in Myelofibrosis - Panel Discussions and a Question-and-Answer session
Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Recent Comments

JOIN THE CONVERSATION
Hey Bluebird,

I understand…
By JanineT GRACE … on
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on